Mixed Phase II results are forcing CytomX to slam the brakes on one of its lead cancer drugs — unless it can convince a partner to help take it further.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,